$80.00
IGF-1 LR3 (Long Arg3 IGF-1) is a recombinant 83 amino acid analogue of human insulin-like growth factor 1. It differs from the native protein by an arginine for glutamic acid substitution at position 3 and a 13 residue extension at the N terminus, and both changes lower its affinity for IGF binding proteins (IGFBPs). It is used as a cell culture supplement and as a research tool in studies of type 1 IGF receptor signalling. This vial contains 1mg.
IGF-1 LR3 is a recombinant analogue of human insulin-like growth factor 1, a single chain of 83 amino acids. Mature native IGF-1 is 70 amino acids. IGF-1 LR3 adds a 13 residue extension at the N terminus (MFPAMPLSSLFVN) and substitutes arginine for glutamic acid at position 3 of the IGF-1 sequence. Both modifications lower its affinity for IGF binding proteins, which is the reason it is used in cell culture in place of native IGF-1.
Recombinant human IGF-1 itself exists as an approved medicine. Mecasermin, sold as Increlex, was first approved in the United States in 2005 for growth failure in pediatric patients with severe primary IGF-1 deficiency or growth hormone gene deletion. Mecasermin is the unmodified 70 amino acid human sequence with three intramolecular disulfide bridges. IGF-1 LR3 is a different molecule. It is not mecasermin, it is not an approved medicine, and the material supplied here is a research chemical.
Technical Specifications
Research Context
Areas that have been examined in the published literature include:
These are observations in laboratory models and should not be read as describing effects in a person or an animal outside a controlled study.
Storage and Handling
Testing and Quality Control
Every batch of IGF-1 LR3 1mg is released against the following checks:
For laboratory research use only. Not for human or veterinary use.
Further reading